Four offers and a call from Bourla: How Pfizer narrowly beat out rival bidder to swallow GBT and its sickle cell drugs for $5.4B – Endpoints News

Four offers and a call from Bourla: How Pfizer narrowly beat out rival bidder to swallow GBT and its sickle cell drugs for $5.4B Endpoints News